All News

Resmetirom is the first-ever drug to be approved anywhere for management of the progressive liver disease.

Your daily dose of the clinical news you may have missed.

THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.

The KDIGO 2024 CKD Practice Guideline is the first update since the 2012 iteration and so is based on the newest research on treatment and technology available.

In a survey of adults aged 50-80 years, 57% of those who reported taking aspirin regularly said they do not have a history of CVD.

Ionis reports the first clinical evidence that DGAT2 inhibition-driven reduction of hepatic fat correlates with improvements in MASH histologic endpoints.

Your daily dose of the clinical news you may have missed.

Primary care plays an essential role in identifying CKD, monitoring and slowing disease progression, and providing timely referral, when indicated, to nephrology.

The 2 phase 3 trials in the 89bio ENLIGHTEN clinical trial program will evaluate the safety and efficacy of the FGF21 analog in MASH, fibrosis.

Even activity levels considered "insufficient" by guideline standards were found protective against stroke in this new systematic review and meta-analysis.

Your daily dose of the clinical news you may have missed.

A CPT code for time spent petitioning insurance companies to approve patient prescriptions has been proposed before; sentiment was not unanimous.

Study participants self-identified as Black, White, or Asian and significant proportions reached improvement of ≥75% in EASI in both in ADORING 1 and ADORING-2.

Findings support current CDC recommendations that all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.

Your daily dose of the clinical news you may have missed.

Melatonin products, particularly flavored gummies and tablets, were documented in 7 out of 10 ED visits for unsupervised medication exposure in children aged ≤5 years.

The label expansion for semaglutide, based on the SELECT trial, includes data showing reduced risk of CV death of 15% and of death from any cause of 19%.

Few participants with dyslipidemia received lipid-lowering medications despite high prevalence, reported authors of the Strong Family Heart Study.